Press releases
- Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy
- Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
- Alpine Immune Sciences to Present Updated Clinical Data for Povetacicept in IgA Nephropathy at the World Congress of Nephrology 2024
- Alpine Immune Sciences Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024
- Alpine Immune Sciences to Participate in Upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
- Alpine Immune Sciences Provides Corporate Update and Full Year 2023 Financial Results
- Alpine Immune Sciences to Report Fourth Quarter and Full Year 2023 Financial Results
- Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences
More ▼
Key statistics
As of last trade Alpine Immune Sciences Inc (34LA:MUN) traded at 60.50, -0.82% below its 52-week high of 61.00, set on Apr 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 60.50 |
---|---|
High | 60.50 |
Low | 60.50 |
Bid | 60.00 |
Offer | 61.00 |
Previous close | 60.50 |
Average volume | 47.78 |
---|---|
Shares outstanding | 65.55m |
Free float | 62.50m |
P/E (TTM) | -- |
Market cap | 4.23bn USD |
EPS (TTM) | -0.6827 USD |
Data delayed at least 15 minutes, as of May 02 2024 07:04 BST.
More ▼